<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704896</url>
  </required_header>
  <id_info>
    <org_study_id>PROVALF</org_study_id>
    <nct_id>NCT03704896</nct_id>
  </id_info>
  <brief_title>PRospective Observational Multicentre Study on VAriability of Lung Function in Stable PCD Patients</brief_title>
  <acronym>PROVALF-PCD</acronym>
  <official_title>PRospective Observational Multicentre Study on VAriability of Lung Function in Stable PCD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cyprus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Meyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using routinely collected clinical data, this study aims to quantify intra-individual (i.e.&#xD;
      in the same individual) variations between measurements of lung function in stable patients&#xD;
      with primary ciliary dyskinesia (PCD), a rare genetic disease that causes lung damage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Lung function measurements are commonly used in PCD to monitor disease progression.&#xD;
      Spirometry measurements are taken every 3 months and results are compared to established&#xD;
      references, adjusted for age, height and ethnicity. Results are also compared to previous&#xD;
      measurements from the same patient at earlier appointments. However, little is understood of&#xD;
      the impact of intra-individual variability and the extent of spontaneous variations in these&#xD;
      comparisons.&#xD;
&#xD;
      One of the priorities for respiratory research in the UK is to understand factors involved in&#xD;
      determining different outcomes for lung function.[1] The precision of measurements done on&#xD;
      the same individual conducted by different people, in different settings and using different&#xD;
      equipment is not entirely known. Importantly, previous studies in healthy children assessing&#xD;
      intra-individual variability have shown variations of up to 1.2 z-scores in spirometry&#xD;
      parameters over the course of 1 year.[2] Within test-variability and daily repeatability can&#xD;
      range from 2 to10% FEV% predicted in young healthy children.[3],[4]&#xD;
&#xD;
      In PCD, deterioration of lung function does not follow a pre-defined pattern.[5] However,&#xD;
      none of the published studies on lung function in PCD to date have taken into consideration&#xD;
      the imprecision of individual and repeated measurements on the same individual over time.&#xD;
      Personal experience and unpublished small retrospective assessments suggest that there is&#xD;
      considerable variability.&#xD;
&#xD;
      Key research question&#xD;
&#xD;
      Quantify intra-individual (i.e. in the same individual) variations between measurements of&#xD;
      lung function in stable patients with primary ciliary dyskinesia (PCD), a rare genetic&#xD;
      disease that causes lung damage.&#xD;
&#xD;
      Study design&#xD;
&#xD;
      Prospective multicentre cohort study using routinely collected clinical data to evaluate&#xD;
      natural variability of lung function measurements in stable PCD patients.&#xD;
&#xD;
      The primary end-point is to assess intra-individual variations between repeated measures of&#xD;
      lung function parameters. Secondary end-points include: a) Inter-individual variations&#xD;
      between repeated measures of lung function parameters and correlations with baseline&#xD;
      measures; b) intra- and inter-individual variation between repeated measures of lung function&#xD;
      parameters during exacerbation.&#xD;
&#xD;
      Participants will be approached by their clinicians and asked to sign a consent form to allow&#xD;
      for their anonymised routinely collected clinical data to be entered into the study. Routine&#xD;
      clinical data will be collected at PCD follow-up clinics in participating centres. These data&#xD;
      are already collected for clinical purposes and will be anonymised locally. Non-identifiable&#xD;
      data will be entered into the study database by a member of the clinical team of the&#xD;
      participating centre. The study coordinating centre (University of Southampton) will only&#xD;
      have access to the anonymised dataset.&#xD;
&#xD;
      The data collection period will last 18 months (6 months for patients recruitment and 12&#xD;
      months for patient follow-up).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-individual variability of FEV1 z-scores</measure>
    <time_frame>up to one-year follow-up period</time_frame>
    <description>Natural intra-individual variability of FEV1 z-score in patients that are not experiencing an episode of chest exacerbation at the time of lung function measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-individual variability of FEV1 z-scores</measure>
    <time_frame>up to one-year follow-up period</time_frame>
    <description>Inter-individual variations between repeated measures of lung function parameters.</description>
  </secondary_outcome>
  <enrollment type="Actual">451</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lung function measurement</intervention_name>
    <description>Spirometry-derived lung function measurements</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with PCD under regular follow-up at one of the centres participating in&#xD;
        the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children (&gt;5 years of age) and adults being follow-up for PCD&#xD;
&#xD;
          -  Availability of at least minimal dataset (spirometry data), at least every 6 months&#xD;
&#xD;
          -  Outpatients and/or in-patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 5 years of age&#xD;
&#xD;
          -  Regular interval between spirometry testing &gt; 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised centre-specific data will be shared between PROVALF-PCD study and prospective PCD registry and retrospective iPCD cohort, where specifcially requested by centre contributing with data. All parties involved in data transfer will sign an agreement with PROVALF-PCD prior to any data transfer.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Throughout the study, when requested; and at the end of the study, if requested.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

